Second Gamma Knife Treatment for Trigeminal Neuralgia: Anterior Target Spacing and 25 Gy as the Second Dose

Bianca S. Marquez 1, 2, Ashley Nguyen 1, Sammie Coy 3, Beatriz Amendola 3, Aizik L. Wolf 1

1. Department of Neurosurgery, Miami Neuroscience Center at Larkin, South Miami, USA  
2. Surgery, Albert Einstein Medical Center Philadelphia, Philadelphia, USA  
3. Radiation Oncology, Innovative Cancer Institute, South Miami, USA

Corresponding author: Aizik L. Wolf, aizikwolf@hotmail.com

Abstract

Objective
Gamma Knife® radiosurgery (GKRS) has been demonstrated to be a well-known approach for treating patients with medical refractory trigeminal neuralgia (TN). Herein, the authors review the outcomes of pain among a large cohort of patients who had undergone a second GKRS delivered at a significantly reduced dose.

Methods
The authors conducted a prospective analysis of patients who have undergone two GKRS procedures between the years 2012 to 2021 at one institution. Baseline characteristics, radiosurgical dosimetry and technique, pain outcomes, and adverse effects were reviewed. Pain outcomes were measured with the Barrow Neurological Institute (BNI) pain intensity scale, which included the best BNI attained after the last treatment and recurrence.

Results
A total of 202 patients were identified, including 55 males and 147 females. Pain recurrence was reported in all patients prior to the second GKRS treatment (median = 4 months). Pain recurrence in the preceding Japan Neuroscience Society (JNS) 2021 study was also reported in all patients after each GKRS with a median value of 20 months between the second and third procedures. Complete to partial pain relief (BNI ≤ III) was achieved in 80% of patients after the second treatment. Over a median of 12 months of follow-up, 60% of patients maintained complete to partial pain relief compared to 77% of patients over the course of three treatments. In the present study, one patient developed facial spasms while 10 patients experienced persistent facial tingling. Subjective mild numbness was also found to be present in 16% of patients, with only 2% being bothersome, as compared to the JNS study, where subjective mild numbness was found to be present in 14%, with only 14.3% being bothersome. Among the 202 patients, 74 (37%) patients had undergone subsequent additional procedures such as a third GKRS, microvascular decompression (MVD), or other percutaneous procedures.

Conclusion
The authors describe the largest study to date of patients undergoing a second GKRS treatment for type 1 medical refractory trigeminal neuralgia. A reduced dose of radiation for a second treatment may produce outcomes similar to those of three consecutive treatments in regard to limiting recurrence and adverse effects.

Introduction
Trigeminal neuralgia (TN) is a rare facial pain disorder characterized by severe unilateral "electric shock-like" pain in one or more divisions of the trigeminal nerve. Type I TN is characterized by episodic attacks while type II TN is characterized by persistent facial pain [1]. While a wide variety of medical and surgical treatments have been developed to treat TN, the recurrent nature of the disease makes long-term relief a challenge.

Gamma Knife® radiosurgery (GKRS) is a well-studied, noninvasive treatment modality for medically refractory and high-risk surgical TN patients [2-4]. Like many treatment options, GKRS provides excellent pain relief but fewer permanent complications [5]. Patients who experience pain relapse with a previous favorable response to an initial GKRS can be selected for a second GKRS treatment [6]. Evidence from prior
studies indicates that a second GKRS treatment may give sustained pain relief but also results in increased toxicity, often leading to facial numbness [6-8].

In the present study, we determine the clinical outcome of patients with type 1 TN that underwent two GKRS treatments, which accounts for the largest study to date. Additionally, we explore the significance of decreasing the dosage of the second GKRS treatment on pain relief durability and toxicity.

Materials And Methods

Patient population

We performed a prospective review of patients who had undergone two GKRS procedures for type 1 medically refractory TN between the years 2012 and 2021 at the Miami Neuroscience Center at Larkin Community Hospital. An initial cohort of 226 patients was identified using electronic health records. We excluded patients with incomplete records (n = 1) and type 2 trigeminal neuralgia (n = 23). The final cohort comprised 202 patients. All patient interactions were reviewed from documentation within the electronic health records. Data pertaining to demographics, past medical history, radiosurgical technique, age at second treatment, pertinent procedures before the initial GKRS, pertinent past medical history, pain outcomes, and postoperative adverse effects were all collected from the electronic health records. This study was approved by the Larkin Community Hospital International Review Board (LCH IRB) (F-0822CSW).

Radiosurgical Procedures

GKRS treatments were performed on a Leksell model G by a team consisting of a neurosurgeon and a medical physicist. The head frame was placed by the neurosurgeon under local anesthesia. Dose selection and anterior target shift were performed on Leksell computerized software. A max initial dose of typically 38–40 Gy at least 1 mm anterior to the 50% isodose line within the dorsal root entry zone was delivered for the first treatment. A max dose of 25 Gy was delivered for the second treatment. The volumes for each procedure were calculated from the computerized software. The 50% isodose line was typically tangential to the brainstem for all patients. Imaging with MRI or CT cisternogram was performed using axial sequences.

Statistical Analysis

Data collection was performed using Microsoft Excel (Microsoft Corporation, Redmond, WA). Descriptive statistics pertaining to patient baseline characteristics, radiosurgical parameters, and treatment outcomes were categorized into tables. Pain intensity after the second GKRS procedure and at the last follow-up after the second GKRS was categorized using the Barrow Neurological Institute (BNI) scale [9]. Complete pain relief with no medication required was defined as a score of I. Occasional pain was defined as a score of II if no medication was required and III if the pain was controlled with medication. Some pain, not adequately controlled with medication, was defined as a score of IV. No pain relief or severe pain was defined as a score of V. Treatment failure after the second GKRS treatment was defined by pain recurrence with a BNI score of IV or V at the last follow-up.

Postoperative adverse effects were categorized into tables. The adverse outcomes were grouped according to symptoms, including facial tingling, spasms, and numbness. Facial numbness was grouped into two categories: mild and bothersome. All adverse effects were counted as subjective in nature because the symptoms were mostly patient-declared.

No statistical tests determining statistical significance were performed. Descriptive statistics pertaining to baseline characteristics and treatment outcomes were tabulated as frequency. Categorical (age) and continuous (duration) data were tabulated as a median with a corresponding interquartile range. Dosimetric data were performed in the same manner.

Results

Patient demographics

Demographic and baseline characteristics are shown in Table 1. The median age at the time of the second GKRS was 70 years. Our sample contained 55 males and 147 females. Prior to GKRS procedures, all patients had well-described recurrent episodic pain in one or more distributions of the face. Seven out of the 202 developed bilateral symptoms. One patient had a past medical history of herpes simplex virus while two other patients had a history of herpes zoster. Five patients (2%) had a past medical history of multiple sclerosis. Before the first GKRS, 35 patients (17%) had undergone at least one surgical therapeutic modality, including seven microvascular decompressions (MVDs) and 28 percutaneous procedures such as rhizotomy or balloon compression.
### TABLE 1: Baseline Characteristics

| Variable                                      | Value       |
|-----------------------------------------------|-------------|
| Median age at 2nd GKRS in years (IQR)         | 70 (59-76.75) |
| Male                                          | 55 (27%)    |
| Female                                        | 147 (73%)   |
| Type 1                                        | 202 (100%)  |
| Right                                         | 123 (61%)   |
| Left                                          | 79 (39%)    |
| Bilateral symptoms                            | 7 (3%)      |
| Prior MVD                                      | 7 (3%)      |
| Prior dental                                   | 23 (11%)    |
| Prior peripheral nerve blocks/neurectomies     | 21 (11%)    |
| Prior combinations                            | 6 (3%)      |
| Prior balloon compressions                     | 7 (3%)      |
| MVD b/w GKRS                                   | 8 (4%)      |
| No previous procedures                         | 151 (75%)   |
| HSV/HZV                                       | 3 (1%)      |
| MS                                            | 5 (2%)      |

PMHx = past medical history, MVD = microvascular decompression, HSV = herpes simplex virus, MS = multiple sclerosis

### Pain Relief Outcomes

Using the BNI scoring method, complete to partial pain relief was achieved in 80% of the patients, and 60% maintained long-term relief. Repeat treatments (e.g., additional GKRS) were done when the pain returned, worsened, or remained unchanged from the second GKRS with BNI scores of IV or V. The time intervals (in months) were reported as both a range and a median value for the following: pain recurrence, between the first and second procedure, and the last follow-up. The results are summarized in Table 2.
| Variable                        | Value     |
|--------------------------------|-----------|
| Best BNI: I                    | 5 (2%)    |
| Best BNI: II                   | 1 (0.5%)  |
| Best BNI: III                  | 155 (77%) |
| Best BNI: IV                   | 18 (9%)   |
| Best BNI: V                    | 23 (11%)  |
| FU BNI: I                      | 3 (1%)    |
| FU BNI: II                     | 1 (0.5%)  |
| FU BNI: III                    | 117 (58%) |
| FU BNI: IV                     | 33 (16%)  |
| FU BNI: V                      | 48 (24%)  |
| Time to pain recurrence in months Median (IQR) | 4 (1 - 9) |
| Time between the two GKRS in months Median (IQR) | 15 (6-33) |
| Time to last follow-up in months Median (IQR) | 12 (10.5-36) |
| Subjective Mild facial numbness | 32 (16%)  |
| Bothersome facial numbness     | 5 (2%)    |
| Facial tingling                | 10 (5%)   |
| 3rd GKRS                       | 11 (5%)   |
| MVD                            | 42 (21%)  |
| Balloon Compression            | 18 (9%)   |
| Botox Injection                | 1 (0.5%)  |
| Glycerol Injection             | 0 (0%)    |
| Nerve Block                    | 1 (0.5%)  |
| Peripheral Neurectomy          | 1 (0.5%)  |

**TABLE 2: Pain Relief Scores and Adverse Effects**

| BNI = Barrow Neurologic Institute pain score, FU = follow-up, MVD = microvascular decompression |

**Toxicity**

The most common adverse effects were mild subjective facial numbness, spasms, and tingling. Subjective mild numbness was found to be present in 16% of patients, with only 2% reporting the symptoms as bothersome. Three patients with bothersome numbness achieved and maintained partial alleviation of pain (BNI of III) while two patients in this category failed to achieve or maintain pain alleviation (BNI of IV and V, respectively). One patient experienced spasms and 12 patients experienced tingling. No patients experienced anesthesia dolorosa.

**Dosimetry**

Dosimetric data are depicted in Table 3 with an illustrated example in Figure 1. The median dose delivered at the first procedure was 40 Gy and the median dose delivered at the second procedure was 25 Gy. Both the median volumes for each treatment were calculated to be 0.1 and the total value calculated for the anterior target shift was 0.814.
Variable | Value
--- | ---
Median dose at 1st GKRS in Gy (IQR) | 38 (38-39)
Median dose at 2nd GKRS in Gy (IQR) | 25 (25-25)
Treatment Planning: MRI | 183 (91%)
Treatment Planning: CT w/ cisternography | 17 (8%)
Treatment Planning: Both | 2 (1%)
Median anterior target shift (IQR) | 0.814 (0.814-0.814)
Median Volume: 1st GKRS | 0.1 (0.9-0.1)
Median Volume: 2nd GKRS | 0.1 (0.9-0.1)

**TABLE 3: Dosimetric and Radiosurgical Data**

MRI = magnetic resonance imaging, CT = computerized tomography

---

**FIGURE 1:** Example Outlining the Dosimetric Plan of Two GKRS Procedures to the Right Trigeminal Nerve

GKRS = Gamma Knife® radiosurgery

---

**Additional Procedures**

A subset of patients underwent additional procedures such as third GKRS (5%), MVD (21%), balloon compression (9%), or other percutaneous procedures (0.5%). All these patients did not achieve resolution of pain following the second GKRS. As a result, they were offered, or sought out, other methods of pain relief. The patients (42) who underwent an MVD have, to date, not had any future relapses in pain.

**Discussion**

Despite a wide, diverse selection of medical and surgical management having been well-established, long-term relief remains a challenge because of the recurrent nature of the disease. Evidence from Burchiel et al.
suggests a simple framework for understanding and categorizing TN. Type 1 TN is defined as pain that is episodic while type 2 is defined as pain that is consistently greater than 50% [5,9]. First-line medications include the administration of either carbamazepine or oxcarbazepine. Traditional surgical management involves performing microvascular decompression. While MVDs may have had high rates of resolution of pain postoperatively (80-98%), Lieu et al. report approximately a 10-30% rate of relapse [10,11]. In a systematic review of indicated treatment modalities for TN, Lamberu et al. developed an algorithm for appropriate management based on the type and image-based evidence showing neural compression [12]. Sharma et al. advised MVD (96%) as the best surgical management for type 1 TN while de-emphasizing the use of radiosurgery (71.8%); relative risk of 1.309 (95% CI 1.217-1.409; P <0.001) [13]. While this study undermines radiosurgery as a viable technique, we consider this to be due to the author’s interpretation of the limited evidence presented at the time of publication. Collectively, these two reviews emphasize MVDs’ relative success in patients with clear neurovascular contact and validate the need for Gamma Knife radiosurgery data on pain relief for resistant cases of TN.

Evidence from two recently published works from 2020 and 2021 on the results of having three Gamma Knife procedures suggest that a third procedure reduces relapses and produces comparable effects for long-term pain relief in at least 77% of patients when compared to the initial or second treatments, respectively [14,15]. Higher doses of radiation manifest as axonal damage and edema at higher doses, yet post-radiosurgery inflammation is not evident [14-18]. Both studies predominantly focus on the outcomes of pain relief after three GKRS treatments with incrementally higher doses per repeat treatment. Thus, three or more Gamma Knife treatments may suggest an increased susceptibility to the development of adverse postoperative effects as a result of axonal edema [11,19]. While repeat GKRS has been widely analyzed, to date, no published works have reported the long-term effects or outcomes of a second GKRS with an accompanied dose of at least 25 Gy but less than 40 Gy [11].

Combined findings in the two studies on outcomes of pain relief involving three or more GKRS in a heterogeneous group of patients are subject to the fundamental limitations of small sample size and study design. Our results are thus comparable to studies showing improved and controlled pain relief in patients having at least three procedures (95% and 77%; respectively). We once again highlight the safety and efficacy of having a second GKRS without the need for subsequent treatments in patients with type 1 TN. Herein, lies future opportunities for emerging studies on GKRS effectiveness for recurrence for the type 1 TN population.

This study is subject to the intrinsic limitations of a small sample size and study design. Although this is considered the largest study to date, the reduced sample size precludes the power to detect differences in postoperative outcomes. The single institution and exclusion criteria inherently introduce a selection bias, subsequently limiting the study’s external validity.

Conclusions
We introduce the largest prospective analysis of patients treated with a second GKRS with a reduced dose of radiation for recurrent type 1 TN. Our results suggest that limiting the treatment to two sessions and lessening the radiation is highly effective, with at least 80% of patients gaining complete to partial pain relief. Our results also suggest that in the long term, at least 60% of patients retain complete to partial relief for a median of 12 months. Subjective postoperative numbness was the most common adverse effect. Although all patients with reported mild numbness had concomitant complete or partial pain relief, additional studies are needed to verify the validity of this treatment approach to other patient populations, specifically patients with type 2 TN.

Additional Information
Disclosures
Human subjects: Consent was obtained or waived by all participants in this study. Larkin Community Hospital Institutional Review Board issued approval F-0822CS/AW. The above research project has been approved by Larkin Community Hospital Institutional Review Board (LCH IRB) effective as of date 9/27/2022. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2015; 33:629-808. 10.1177/0333102413485658
2. Marshall K, Chan MD, McCoy TP, et al.: Predictive variables for the successful treatment of trigeminal neuralgia with gamma knife radiosurgery. Neurosurgery. 2012; 70:566-72; discussion 572-3.
3. Pollock BE: Surgical management of medically refractory trigeminal neuralgia. Curr Neurol Neurosci Rep. 2012, 12:125-31. 10.1007/s11910-011-0242-7
4. Régis J, Tulesaca C, Reseguier N, Carron R, Donnet A, Gaudart J, Levivier M: Long-term safety and efficacy of Gamma Knife surgery in classical trigeminal neuralgia: a 497-patient historical cohort study. J Neurosurg. 2016, 124:1079-87. 10.1017/jns.2015.444
5. Kondziolka D, Zorro O, Lobato-Polo J, Kano H, Flannery TJ, Flickinger JC, Lunsford LD: Gamma Knife stereotactic radiosurgery for idiopathic trigeminal neuralgia. J Neurosurg. 2010, 112:758-65. 10.1017/jns.2009.96
6. Huang CF, Tu HT, Liu WS, Chiou SY, Lin LY: Gamma Knife surgery used as primary and repeated treatment for idiopathic trigeminal neuralgia. J Neurosurg. 2008, 109 Suppl:179-84. 10.3171/JNS/2008/12/S27
7. Park KJ, Kondziolka D, Berkowitz O, et al.: Repeat gamma knife radiosurgery for trigeminal neuralgia. Neurosurgery. 2012, 70:295-305; discussion 305. 10.1227/NEU.0b013e318230218e
8. Rogers CL, Shetter AG, Fiedler JA, Smith KA, Han PP, Speiser BL: Gamma knife radiosurgery for trigeminal neuralgia: the initial experience of The Barrow Neurological Institute. Int J Radiat Oncol Biol Phys. 2000, 47:1015-9. 10.1016/s0360-3016(00)000055-7
9. Burchiel KI: A new classification for facial pain. Neurosurgery. 2005, 53:1166-7; discussion 1166-7.
10. Zakrzewska JM, Coakham HB: Microvascular decompression for trigeminal neuralgia: update. Curr Opin Neurol. 2012, 25:296-301. 10.1097/WCO.0b013e328352c465
11. Huang CF, Tu HT, Liu WS, Chiou SY, Lin LY: Gamma Knife surgery used as primary and repeated treatment for idiopathic trigeminal neuralgia. J Neurosurg. 2008, 109 Suppl:179-84. 10.3171/JNS/2008/12/S27
12. Park KJ, Kondziolka D, Berkowitz O, et al.: Repeat gamma knife radiosurgery for trigeminal neuralgia. Neurosurgery. 2012, 70:295-305; discussion 305. 10.1227/NEU.0b013e318230218e
13. Rogers CL, Shetter AG, Fiedler JA, Smith KA, Han PP, Speiser BL: Gamma knife radiosurgery for trigeminal neuralgia: the initial experience of The Barrow Neurological Institute. Int J Radiat Oncol Biol Phys. 2000, 47:1015-9. 10.1016/s0360-3016(00)000055-7
14. Burchiel KI: A new classification for facial pain. Neurosurgery. 2005, 53:1166-7; discussion 1166-7.
15. Lambru G, Zakrzewska J, Matharu M: Trigeminal neuralgia: a practical guide. Pract Neurol. 2021, 21:392-402. 10.1136/practneurol-2020-002782
16. Sharma R, Phalak M, Katiyar V, Borkar S, Kale SS, Mahapatra AK: Microvascular decompression versus stereotactic radiosurgery as primary treatment modality for trigeminal neuralgia: a systematic review and meta-analysis of prospective comparative trials. Neural India. 2018, 66:688-94. 10.4103/0002-3886.235242
17. Gupta M, Saghi V, Mittal A, et al.: Results of three or more Gamma Knife radiosurgery procedures for recurrent trigeminal neuralgia. J Neurosurg. 2021, 135:1789-98. 10.3171/2020.2.JNS192876
18. Helis CA, Hughes RT, Munley MT, et al.: Results of a third Gamma Knife radiosurgery for trigeminal neuralgia. J Neurosurg. 2020, 134:1237-45. 10.3171/2020.2.JNS192876
19. Helis CA, Lukas JT Jr, Boutilier ID, Chan MD, Tatter SB, Laxton AW: Repeat radiosurgery for trigeminal neuralgia. Neurosurgery. 2015, 77:755-61; discussion 761. 10.1227/NEU.0000000000000915
20. Jones GC, Elaimy AL, Demakas JJ, et al.: Feasibility of multiple repeat gamma knife radiosurgeries for trigeminal neuralgia: a case report and review of the literature. Case Rep Med. 2011, 2011:238910. 10.1155/2011/238910
21. Kondziolka D, Lacomis D, Niranjian A, Mori Y, Maesawa S, Fellows W, Lunsford LD: Histological effects of trigeminal nerve radiosurgery in a primate model: implications for trigeminal neuralgia radiosurgery. Neurosurgery. 2000, 46:971-6; discussion 976-7. 10.1097/00006123-200004000-00038
22. Gellner V, Kurschel S, Kreil H, Hall EM, Ofner-Kopeinig P, Unger F: Recurrent trigeminal neuralgia: long term outcome of repeat gamma knife radiosurgery. J Neurol Neurosurg Psychiatry. 2008, 79:1405-7. 10.1136/jnnp.2007.142794